IngredientsXylanase (systematic name: endo-1,4-β-xylanase; EC 3.2.1.8) is a hydrolytic enzyme belonging to the class of carbohydrases. Xylanase is one such enzyme that catalyzes the breakdown of the β-1,4 linkage of xylan, the second most abundant renewable heteropolysaccharide and hemicellulosic constituent of the plant cell wall. The enzyme's primary substrate, xylan, is a complex polymer whose structure has been described as complex, repeated linear polymers of xylopyranosyl groups at numerous carbon positions with different acidic compounds or sugars.
Xylanases are classified under the larger system of glycoside hydrolase (GH) families. Endo-β-1,4-xylanases are the most critical enzymes in the degradation of xylan backbone, breaking the β-1,4 glycosidic bond and producing different types of oligosaccharides, most of which belong to glycoside hydrolase (GH) 10 and 11 families. They differ greatly in their structures, substrate specificity and catalytic mechanism. GH10 xylanases adopt a (β/α)8-barrel fold, while the structures of GH11 xylanases are β-jelly roll. Additional GH families (e.g., GH30) encoding xylanolytic activity have also been characterized. The food enzyme considered in regulatory assessments is typically an endo-1,4-β-xylanase (EC 3.2.1.8).
Xylanases are remarkably widespread in nature. Xylanases are prevalent in nature; they arise both in prokaryotes and eukaryotes and have been reported from marine and terrestrial bacteria, rumen bacteria, protozoa, fungi, marine algae, snails, crustaceans, insects, and seeds of terrestrial plants and germinating seeds. Xylanases are produced by fungi, bacteria, yeast, marine algae, protozoans, snails, crustaceans, insects, seeds, etc.; mammals do not produce xylanases.
Among microbial sources, actinomycetes, fungi, bacteria, and yeast are the principal sources of xylanases. Furthermore, fungi produce higher amounts of xylanase than yeasts or bacteria. The fungal genera commonly producing xylanase include Aspergillus, Coriolus versicolor, Fusarium, Phanerochaete chrysosporium, Trichoderma, Pichia, and Penicillium. Among bacteria, genera such as Micrococcus, Bacillus, Paenibacillus, Staphylococcus, Cellulomonas, Microbacterium, Arthrobacter, Rhodothermus, and Pseudoxanthomonas have been reported for xylanase production. Actinomycetes of the genera Nonomuraea, Streptomyces, and Actinomadura are also reported xylanase producers.
The principal commercial source of xylanases is filamentous fungi. Filamentous fungi are particularly interesting producers of xylanase from an industrial perspective, as they produce extracellular xylanases and other auxiliary enzymes involved in the degradation of xylan into its components. Specific commercially relevant species include Trichoderma reesei, Aspergillus niger, Trichoderma longibrachiatum, Bacillus licheniformis, Bacillus subtilis, and Komagataella phaffii (formerly Pichia pastoris), the latter used as a recombinant expression host.
Reports also describe isolation and purification of xylanase from other sources such as the anaerobic bacterium Clostridium acetobutylicum, immature cucumber seeds, and germinating barley. Additionally, the substrate xylan is itself widely distributed: xylans are present in foods such as whole grains, cereals, seeds, legumes, and certain vegetables, meaning that xylanase plays a key role in the digestion of these foods.
For food, feed, and supplement applications, xylanase is produced commercially by controlled submerged liquid fermentation (SmF) or solid-state fermentation (SSF) of the producing organism, followed by extraction, concentration, and formulation. The SSF system offers many advantages over SmF, such as mimicking the natural habitat of the microorganism, reducing water activity to minimize microbial contamination, providing greater enzyme stability, requiring less energy, producing enzymes with higher specific activities, and simplifying downstream processing.
In dietary supplement contexts, xylanase is most commonly marketed as part of multi-enzyme digestive enzyme blends, available in capsule or tablet form. It may be listed on supplement labels by its systematic name (endo-1,4-β-xylanase), the common name "xylanase," or described by its microbial source (e.g., "xylanase from Trichoderma longibrachiatum"). Enzymes like cellulase, hemicellulase, xylanase, β-glucanase, and pectinase are often grouped as fiber-targeting enzymes in commercial digestive enzyme products. Activity in commercial preparations is expressed in units such as XU (xylanase units) or XBS (xylan-breakdown units per gram), depending on the assay methodology used by the manufacturer or regulatory body.
In the food industry, xylanase preparations are formulated as liquids, granulates, and encapsulated powders designed for use in baking, brewing, and animal feed. DSM, for example, has proposed using xylanase enzyme preparation in baking applications for improved dough handling at up to 27.6 mg total organic solids (TOS) per kilogram of flour, and in beer production to decrease viscosity at up to 6.9 mg TOS per liter of malt.
Xylanase does not have a discrete traditional herbal or folk-medicine history in the manner of plant botanicals. Its recognized utility is rooted in the industrial and food-technology era, beginning in earnest in the second half of the twentieth century. Unlike isolated plant alkaloids or herbal preparations with centuries of ethnobotanical use, xylanase is characterized primarily by its microbial enzyme biochemistry rather than by any traditional healing tradition.
However, the fermented foods and leavened breads central to many traditional diets across Asia, the Middle East, and Europe have historically been prepared by processes that incidentally involve microbial enzyme activity, including xylanolytic activity by the molds and bacteria naturally present during fermentation. The intentional addition of purified xylanase to bread dough is a modern practice. Xylanase has been introduced more recently as it can improve the handling properties of dough, the oven-spring and bread volume; moreover, it has the potential to retard staling, thus increasing the shelf life of bread. Along with first-generation lipases and pure fungal alpha-amylase, xylanase became a valuable tool for bakers who were struggling to replace or significantly reduce levels of potassium bromate and other oxidizing agents.
Xylanase preparations derived from Aspergillus species were introduced to commercial baking during the 1990s. The application of Aspergillus aculeatus xylanase in bread and bakery products was introduced in the mid-1990s. From this industrial entry point, xylanase has subsequently become one of the most widely studied enzyme ingredients relevant to animal nutrition and, more recently, human digestive health.
The substrate of xylanase — xylan and the arabinoxylans found in cereal grains — has been consumed by humans for millennia in the form of whole-grain foods. Xylans are prominent dietary cereal components of the human diet which travel through the gastrointestinal tract as non-digested dietary fibre, since the human genome does not contain xylanolytic enzymes. The gut microbiota, however, digests xylans as a food source, and xylo-oligosaccharides generated in this digestive process have prebiotic health-promoting properties. The concept of exogenously supplementing xylanase to enhance this process is an emerging, contemporary one without documented traditional precedent.
Xylanase catalyzes the breakdown of the β-1,4 linkage of xylan, the second most abundant renewable heteropolysaccharide and hemicellulosic constituent of the plant cell wall. Arabinoxylan (AX) is the most nutritionally relevant form of xylan in cereals: arabinoxylans (AXs) comprise nearly half of the non-starch polysaccharides (NSP) found in corn and corn DDGS, and thus xylanase, a carbohydrase that hydrolyzes the β-1,4-glycosidic bonds of AXs, may mitigate the impact of corn-based NSP.
The members of the GH11 family (also known as "true xylanases") are more specific to unsubstituted xylan substrate, while GH10 xylanases hydrolyze substituted xylan backbone. Generally, GH10 xylanases are reported to attack the glycosidic linkage next to a single or double-substituted xylose toward the non-reducing end and require two unsubstituted xylose residues between branched residues, while GH11 xylanases are said to only hydrolyze glycosidic bonds where the two corresponding xylose moieties in subsites (−1) and (+1) are not branched.
The two GH family endo-xylanases (GH10 and GH11) produce different types of oligosaccharides as hydrolysis products as a result of differences in the cleavage specificities of the enzymes. GH10 xylanases generally release oligomers in which the sugar at the non-reducing end is decorated with methyl-glucuronate, while those from family 11 liberate oligomers with internal methyl-glucuronate substituents during glucuronoxylan degradation.
Xylanase hydrolysis is mediated through the classical Koshland double-displacement mechanism, in which each substrate contributes hydroxyl groups to the stabilization of the transition state, leading to catalysis. The xylanase sequence is composed of one or more non-catalytic carbohydrate-binding modules (CBMs) for xylan recognition and a catalytic domain for hydrolysis. The three-dimensional structures of GH10 and GH11 xylanase have distinct (α/β)8 barrel fold and β-jelly roll fold structures, respectively, with glutamate and aspartate residues in the catalytic site.
The enzymatic action of xylanase upon xylan generates xylooligosaccharides (XOS) and, ultimately, free xylose monosaccharides. Under simulated digestive conditions, xylanase from Trichoderma longibrachiatum was shown to break down fiber and produce natural prebiotics — xylooligosaccharides (XOS) and xylose — which help feed beneficial gut bacteria, such as Bifidobacterium and Bacteroides.
Gut commensal bacteria produce a number of endo β-D-xylanase glycohydrolases (GH 30, 10, 11 and 30) which internally cleave β1–4 glycosidically linked xylopyranose residues of the xylan backbone releasing xylo-oligosaccharides. These xylo-oligosaccharides then act as substrates for a family of β-D-xylosidases which release D-xylose monosaccharide units from the non-reducing termini of xylotriose and xylobiose.
A central, well-documented mechanism of xylanase action in the gastrointestinal tract relates to the viscosity of intestinal digesta. Arabinoxylans in cereal-based diets are major contributors to digesta viscosity, which impairs nutrient absorption by slowing diffusion across the intestinal epithelium. Dietary supplementation of xylanase leads to a decrease in ileal digesta viscosity. This is a consistent finding across multiple animal studies and underpins the use of xylanase as a digestibility-enhancing feed additive.
Additionally, xylanase activity can result in the production of short-chain fatty acids (SCFAs), which provide various gut health benefits, such as gut homeostasis and immune regulation. In broiler studies, dietary supplementation with xylanase led to an increase in the physical barrier as indicated by increased villus height and villus height/crypt depth ratio; levels of D-lactic acid and endotoxin were reduced; and xylanase supplementation also increased the abundance of Muc-2, ZO-1, and Occludin, markers of tight junction integrity.
The largest body of research on xylanase as a dietary supplement concerns its use in animal nutrition — specifically poultry and swine — where the evidence for benefit is substantial but does not directly translate to verified human physiological outcomes.
In a controlled broiler study, dietary xylanase supplementation in wheat-based diets was evaluated for performance and functional digestive parameters including ileal digesta viscosity, apparent ileal digestibility, intestinal morphology and microflora, digestive enzyme activities, and excreta odor content in 600 one-day-old Ross 308 male broilers supplemented with 0, 1,875, 3,750, and 5,625 XU/kg xylanase. Xylanase supplementation improved body weight gain and decreased the feed conversion ratio during days 1 to 18 and for the duration of the experiment. In addition, inclusion of xylanase increased Lactobacillus numbers in the ileum and cecum, while decreasing ileal and cecal E. coli counts.
In pig nutrition, a controlled study found that increasing xylanase supplementation from 0 to 1,400 LXU/kg enhanced ileal digestibility of NDF from 27.9 to 40.3%, dry matter from 55.4 to 64.6%, organic matter from 59.2 to 67.7%, and energy from 58.8 to 68.0%. A separate pig study reported that xylanase increased total tract energy digestibility of a millrun diet from 72.1 to 78.9%, digestible energy content from 3.19 to 3.51 Mcal/kg of dry matter, and dry matter digestibility from 71.5 to 78.6%.
A broader review on xylanase supplementation in corn-based swine diets noted that the efficacy of xylanases when used in corn-based pig diets is highly variable. This variability reflects the complexity of dietary substrate composition, enzyme dose, and individual animal factors.
Evidence strength: The animal nutrition evidence base is extensive, spanning hundreds of controlled feeding studies in poultry, pigs, and other species. Consistent improvements in nutrient digestibility, intestinal morphology, and microflora balance have been demonstrated. This evidence informs the biological plausibility of xylanase supplementation in humans but does not constitute direct clinical evidence for human benefit.
Direct human clinical evidence for orally supplemented xylanase enzyme as a dietary supplement is sparse. Most of the solid evidence for fiber-targeting enzymes such as xylanase comes from animal nutrition and in vitro studies, not human clinical trials. Human data is sparse and usually limited to broader multi-enzyme products where these fiber-targeting enzymes are not isolated.
An in vitro study using the INFOGEST static digestion model examined a xylanase enzyme derived from Trichoderma longibrachiatum. The INFOGEST in vitro Static Digestion Model demonstrated significant XOS production from substrates like wheat bran and bulgur wheat, with less activity on less viscous foods. The authors recognized that xylanase's potential to increase prebiotic availability in plant-based diets warrants further investigation, including human clinical trials to assess its efficacy in the human gastrointestinal tract.
Evidence strength: At present, human-specific clinical evidence for orally supplemented xylanase as a dietary supplement is extremely limited. In vitro and animal data indicate a plausible mechanism for enhanced fiber digestion and prebiotic generation, but randomized controlled trials in humans specifically evaluating xylanase supplementation have not been published in the peer-reviewed literature to date.
Although clinical research has not directly tested xylanase enzyme supplements in humans for microbiome modification, the downstream products of xylanase activity — XOS — have been studied in human trials. This is relevant because a key proposed mechanism of dietary xylanase supplementation is the in situ generation of XOS within the gut.
Xylooligosaccharides (XOS), derived from lignocellulosic biomass, have emerged as promising prebiotics due to their ability to selectively modulate gut microbiota and confer various health benefits. XOS are composed of β-D-xylopyranose units linked by β-glycosidic bonds and are resistant to mammalian digestion but fermentable by beneficial gut bacteria. Research results indicate that XOS enhance the growth of probiotics, having a bifidogenic effect, which stimulates the production of short-chain fatty acids (SCFAs), and suppress the proliferation of pathogens. In vitro and in vivo studies demonstrate their potential to alleviate metabolic disorders, improve lipid profiles, reduce inflammation, and restore gut homeostasis.
A key human randomized controlled trial evaluated XOS supplementation in 32 healthy adults. Healthy adult subjects (n = 32) were recruited in a double-blind, randomized, placebo-controlled study; subjects received 1.4 g XOS, 2.8 g XOS or placebo in daily doses. The study consisted of a 2-week run-in, an 8-week intervention, and a 2-week washout phase. XOS was tolerated without significant gastrointestinal side effects. Bifidobacterium counts increased in both XOS groups compared to the placebo subjects; the 2.8 g per day group showed significantly greater increases than the 1.4 g per day group. Total anaerobic counts and Bacteroides fragilis group counts were significantly higher in the 2.8 g per day XOS group. A separate pilot study also reported that XOS at the dose of 2.8 g/day was well tolerated and modified the gut bacterial composition in healthy people.
Mechanistic research has elucidated how gut bacteria deploy xylanases endogenously. In xylan-rich dietary interventions in adult humans, levels of endogenous Bifidobacterium pseudocatenulatum increased only when the endo-1,4-β-xylanase gene (BpXyn10A) was detected in the organism, indicating that xylan availability is a fitness determinant in the human gut.
Evidence strength: The evidence that exogenously produced XOS has prebiotic effects in humans (increased Bifidobacterium populations, SCFA production) is moderate and supported by at least one well-designed randomized controlled trial, as well as multiple smaller human studies and mechanistic in vitro data. However, the evidence for an orally administered exogenous xylanase enzyme supplement generating equivalent XOS in the human gastrointestinal tract — and thereby replicating these effects — remains at the in vitro/pre-clinical stage. A causal chain from enzyme supplement to XOS generation to microbiome benefit in humans has not yet been directly demonstrated in published human trials.
In vitro and in vivo studies demonstrate the potential of XOS (generated by xylanase activity) to alleviate metabolic disorders, improve lipid profiles, reduce inflammation, and restore gut homeostasis. These findings are largely preclinical. In broiler chickens, supplementation of xylanases had a great effect on the degradation of arabinoxylan from wheat, which led to a relatively greater reduction in ileal digesta viscosity, and supplementation of bile acid and xylanase linearly increased fat digestibility of birds fed wheat and tallow diets. Direct human metabolic data are not available from xylanase supplementation studies.
Research into XOS in the context of inflammatory bowel disease has been conducted at the level of in vitro fermentation models. A study examining XOS in ulcerative colitis enrolled five patients with UC in clinical remission and five healthy volunteers; fresh fecal samples were diluted and inoculated in medium alone or with XOS, and after fermentation for 48 h, samples were collected for 16S rDNA sequencing to investigate the gut microbiota composition. This was an in vitro fermentation model, not a clinical trial, and therefore does not demonstrate direct clinical benefit of xylanase or XOS supplementation in IBD.
In an in vivo colitis mouse model, XOS solutions with higher contents of short-chain xylobiose and xylotriose fractions demonstrated enhanced efficacy against intestinal inflammation. These animal and in vitro findings support further clinical investigation but do not establish clinical efficacy.
Evidence strength: Preclinical (in vitro and animal model) only for inflammatory conditions. No published human clinical trials for this indication at the time of writing.
The most robustly characterized application of xylanase is in the baking industry, where extensive research has been conducted on its functional effects in dough and bread quality. In the baking process, xylanase is added to the dough to convert water-insoluble hemicellulose into a water-soluble form, which helps improve the rheological properties of the dough. Xylanase has gained immense interest in the baking industry for its role in improving dough attributes and bread quality. These improvements include increased volume, more uniform and finer crumbs, and decreased dough firmness. Moreover, it has the potential to retard staling, thus increasing the shelf life of the bread.
Xylanases have long been used in the baking industry for improving dough stability and flexibility and for increasing bread volume and crumb structure. Only xylanases from glycoside hydrolase families 10 and 11 appear to have been tested in this application.
Xylanase for human dietary supplementation is available primarily as part of multi-enzyme blends in capsule or tablet form. Xylanase activity is expressed in various units depending on context and manufacturer assay method, including XU (xylanase units), XBS units, or BXU. Standardization across products is not uniform.
In animal feed research — the best-controlled dosing literature available — supplementation levels tested in broiler wheat-based diets were 0, 1,875, 3,750, and 5,625 XU/kg of diet. In another broiler study, male chicks were assigned to wheat-based diet treatments adding 0 mg/kg (control), 50 mg/kg, 100 mg/kg, and 150 mg/kg of xylanase. In a pig study, xylanase supplementation from 0 to 1,400 LXU/kg was evaluated. In corn-based broiler diets, levels of 2,000 U/kg and 3,000 U/kg xylanase were tested in 80 kcal/kg and 100 kcal/kg energy-deficient diets, respectively.
For food processing applications in baking, xylanase enzyme preparation has been proposed for use at up to 27.6 mg total organic solids per kilogram flour.
In the human XOS clinical trials most relevant to the downstream mechanism of xylanase, subjects received 1.4 g XOS or 2.8 g XOS per day in daily doses. No published human clinical studies have established a standardized effective dose of exogenous xylanase enzyme supplement in humans for health outcomes.
Xylanase has been subject to formal safety evaluation by both the US Food and Drug Administration (FDA) and the European Food Safety Authority (EFSA). Based on information provided and information available to FDA, the agency has indicated no questions regarding the conclusion that a xylanase enzyme preparation is GRAS (Generally Recognized As Safe) under the intended conditions of use. Conformity of these preparations with specifications established in the Food Chemicals Codex and the General Specifications for Enzyme Preparations Used in Food Processing established by the FAO/WHO Joint Expert Committee on Food Additives (JECFA) has been documented.
Under EU law, all food enzymes currently on the EU market, as well as all new food enzymes, shall be subjected to a safety evaluation by EFSA and approval via an EU Community list. EFSA's FEEDAP Panel has evaluated multiple commercial xylanase preparations as zootechnical feed additives and digestibility enhancers. For example, the FEEDAP Panel concluded that one xylanase/β-glucanase combination (ENZY CARBOPLUS®) is safe for all poultry, and its use is considered safe for consumers and the environment. Similarly, there is no evidence that would lead the EFSA FEEDAP Panel to reconsider previous conclusions that approved xylanase additives remain safe for the animal species/categories, the consumer, and the environment under the authorised conditions of use.
EFSA's Panel has considered that there are no indications for food allergic reactions to endo-1,4-β-xylanase by dietary exposure. As a protein, xylanase is subject to degradation by proteases in the gastrointestinal tract, which substantially reduces systemic exposure. Regulatory bodies have generally concluded that oral ingestion of xylanase at food-additive levels does not present a safety concern for healthy consumers.
A documented and source-backed safety concern specific to xylanase relates to occupational respiratory sensitization, particularly among bakers. Respiratory allergy, e.g. baker's asthma, following occupational exposure to xylanase has been described in some epidemiological studies and case reports. A landmark case report confirmed that an asthmatic baker showed IgE-mediated sensitization to xylanase of Aspergillus niger used as a baking additive, and inhalative challenge with approximately 0.5 µg of the enzyme resulted in an immediate-type asthmatic reaction. This was characterized as a relevant type I-sensitizer in the baking industry.
A more complex case demonstrated that allergy to xylanase and cellulase was demonstrated by skin prick test, EAST, immunoblot and specific bronchial challenge. No sensitization to alpha-amylase could be demonstrated, but there was a weak flour allergy as documented by EAST and immunoblot, and a positive occupational-type challenge with high concentrations of rye flour. This indicates that xylanase occupational allergy can occur independently of sensitization to other common baking allergens.
With respect to oral versus inhalation risk, several studies have shown that adults with occupational asthma can ingest respiratory allergens without acquiring clinical symptoms of food allergy. However, the likelihood of an allergic reaction upon oral ingestion of xylanase in individuals respiratory-sensitized to xylanase cannot be excluded, but the likelihood of such a reaction occurring is considered to be low.
EFSA's FEEDAP Panel concluded that the xylanase additive is not irritant to skin but should be considered as a possible eye irritant and, in common with other proteinaceous substances, a respiratory sensitiser. These concerns pertain primarily to occupational handling of powdered preparations, not to oral ingestion by consumers.
EFSA routinely assesses the allergenicity of xylanase preparations by comparing amino acid sequences to known allergen databases. The potential allergenicity of one xylanase preparation was assessed by comparing its amino acid sequence with those of known allergens; using higher than 35% identity in a window of 80 amino acids as the criterion, no matches were found for that particular preparation. Results vary by production organism and specific protein sequence; each preparation requires individual assessment.
Xylanases considered for applications are of fungal or bacterial origin which show optimum activity at, or near, mesophilic temperatures (~40–60 °C). The human gastrointestinal environment — with acid pH in the stomach and protease activity throughout — may significantly reduce the activity of orally consumed xylanase before it reaches the small intestine. Thermostable variants and encapsulated delivery systems have been developed to address enzyme stability in food and feed applications. For human dietary supplements, the question of how much enzymatic activity survives gastric transit to reach the small intestine in an active form remains incompletely characterized in the published clinical literature.
No specific drug-enzyme interactions with orally supplemented xylanase have been described in the peer-reviewed clinical literature. As a protein-based enzyme supplement, xylanase is not known to inhibit cytochrome P450 drug-metabolizing enzymes. Its activity is substrate-specific (arabinoxylans in plant cell walls), limiting the scope of unintended biochemical interactions. However, by altering fiber digestion and gut microbiota composition — potentially increasing SCFA production and modulating intestinal transit — xylanase supplementation could in principle influence the bioavailability or absorption of other nutrients or orally administered drugs, though no such interactions have been directly documented in human studies.
The scientific evidence profile for xylanase as a human dietary supplement is characterized by a substantial and well-replicated base of animal nutrition research, a smaller but growing body of human evidence for the prebiotic effects of its downstream products (XOS), and a near-complete absence of human randomized controlled trials testing the enzyme itself as a supplement. The implications on intestinal homeostasis and metabolic response warrant further clinical review, with emphasis on specific gut microbes and the complexity of xylan structure to provide a clue for the inconsistent results in human studies.
Dietary xylans are thus emerging therapeutic compounds warranting further study in novel disease prevention protocols. The broader context of xylan biology in the human gut — mediated through microbial xylanases endogenously — is becoming better understood, providing a scientific rationale for the hypothesis that exogenous xylanase supplementation could confer benefits. Formal human clinical trials are required to characterize the dose-response relationship, optimal delivery form, and clinical endpoints for supplemental xylanase in human health.
Health conditions that Xylanase may help support.
Undigested xylan fiber in the colon undergoes rapid bacterial fermentation, producing excess gas and symptoms such as bloating and abdominal pain. Xylanase supplementation is proposed to begin xylan hydrolysis earlier in the digestive tract, reducing the fermentable substrate load delivered to the colon. Human evidence is mechanistic and extrapolated from broader digestive enzyme research; dedicated xylanase-specific human RCTs are lacking. Innerbody's 2026 evidence review notes that solid human clinical data for fiber-targeting enzymes like xylanase remains sparse.
Xylanase degrades xylan, a major hemicellulosic polysaccharide in cereal grain cell walls and plant foods. It is included in broad-spectrum digestive enzyme supplements to improve digestion of plant-based foods and reduce fermentable substrate. Clinical evidence supports its use as part of multi-enzyme formulations for digestive health.
Xylanase hydrolyzes dietary xylans into xylooligosaccharides (XOS), which selectively promote the growth of beneficial gut bacteria such as Bifidobacterium and Bacteroides. A 2025 Food Chemistry study demonstrated that a GH11 xylanase from Trichoderma longibrachiatum produced prebiotic XOS under simulated gastrointestinal conditions. XOS fermentation by colonic microbiota generates short-chain fatty acids (SCFAs) that further support microbial homeostasis. Human RCT data on XOS supplementation confirms bifidogenic and microbiome-modulating effects.
Animal studies show xylanase supplementation increases expression of intestinal tight junction proteins including ZO-1, occludin, and MUC-2, markers of epithelial barrier integrity. XOS produced by xylanase hydrolysis drive SCFA production in the colon, and SCFAs are established regulators of tight junction assembly and intestinal barrier function. No direct human clinical trials of xylanase specifically for leaky gut have been conducted.
Body systems that Xylanase may help support.
Go back